Cash totaled $13.2 million on a March 31 pro forma basis.
Shares outstanding were listed as 33,553.
Halneuron Phase 2b timeline outlined
Dogwood Therapeutics investor presentation outlined a non-opioid pain pipeline led by Halneuron injection for chemotherapy-induced neuropathic pain.
Halneuron Phase 2b data readout is targeted for fall; FDA end-of-Phase 2 submission is planned for Q4.
The program is positioned around Nav1.7 sodium-channel blockade using tetrodotoxin, designed for peripheral pain modulation without central nervous system effects.
DWTX•
